Mometasone Furoate is medium potency corticosteriod indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. Like other topical corticosteriods,Mometasone Furoate has anti-infalmmatory, anti pruritic, and vasoconstrictive properties. The total sales for the two Mometasone Furoate products in the 12 month period ending March 2008 were in excess of $29 million as per IMS Health.
Mometasone will be manufactured at Glenmark's Baddi facility in India.It has recently received US FDA approval for its manufacturing plant at Baddi, Himachal Pradesh. The US FDA approval will now enable Glenmark to enter the niche segment of semi-solid dosages in most of the regulated markets of the world.
